8 results on '"Malinverno M."'
Search Results
2. Cooperative Localization Enhancement through GNSS Raw Data in Vehicular Networks
- Author
-
Minetto, A., Zocca, S., Raviglione, F., Malinverno, M., Casetti, C. E., Chiasserini, C. F., and Dovis, F.
- Subjects
cooperative awareness ,V2X ,cooperative positioning ,GNSS observables ETSI ITS-G5 ,automotive ,Global Navigation Satellite Systems ,GNSS raw data ,Global Navigation Satellite Systems, GNSS raw data, GNSS observables ETSI ITS-G5, automotive, cooperative awareness, cooperative positioning, V2X - Published
- 2021
3. Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial
- Author
-
Lanfranconi, S., Scola, E., Bertani, G. A., Zarino, B., Pallini, Roberto, D'Alessandris, Quintino Giorgio, Mazzon, E., Marino, S., Carriero, M. R., Scelzo, E., Farago, G., Castori, M., Fusco, C., Petracca, A., D'Agruma, L., Tassi, L., D'Orio, P., Lampugnani, M. G., Nicolis, E. B., Vasami, A., Novelli, D., Torri, V., Meessen, J. M. T. A., Salman, R. A. -S., Dejana, E., Latini, R., Pignotti, Fabrizio, Sturiale, Carmelo Lucio, Albanese, Alessio, Valcamonica, G., Ronchi, D., Pogliani, S., De Grazia, U., Bossi, C., Ciurleo, R., Raggi, P., Simeone, A., Balconi, G., Foresta, A., Buratti, M. G., Carrara, M., Ojeda-Fernandez, M. L., Treglia, R., Maggioni, A. P., Beghi, E., Tettamanti, M., Regna-Gladin, C., Prelle, A., Mangiavacchi, M., Poloni, M., Lazzaroni, F., Malinverno, M., Ungaro, C., and Raucci, F.
- Subjects
Male ,Hemangioma, Cavernous, Central Nervous System ,Pediatrics ,medicine.medical_treatment ,Settore MED/27 - NEUROCHIRURGIA ,Medicine (miscellaneous) ,Anxiety ,Severity of Illness Index ,law.invention ,Study Protocol ,Mice ,0302 clinical medicine ,Randomized controlled trial ,law ,Medicine ,Pharmacology (medical) ,Prospective Studies ,Depression (differential diagnoses) ,0303 health sciences ,lcsh:R5-920 ,medicine.diagnostic_test ,Depression ,Propranolol ,Treatment Outcome ,Italy ,Models, Animal ,Disease Progression ,Female ,Epileptic seizure ,Safety ,medicine.symptom ,lcsh:Medicine (General) ,Intracranial Hemorrhages ,medicine.drug ,Adult ,medicine.medical_specialty ,Adrenergic beta-Antagonists ,Radiosurgery ,03 medical and health sciences ,Magnetic resonance imaging ,Cerebral cavernous malformation ,Animals ,Humans ,Adverse effect ,030304 developmental biology ,business.industry ,Case-Control Studies ,Quality of Life ,Nervous System Diseases ,business ,030217 neurology & neurosurgery - Abstract
Background Cerebral cavernous malformations (CCMs) are vascular malformations characterized by clusters of enlarged leaky capillaries in the central nervous system. They may result in intracranial haemorrhage, epileptic seizure(s), or focal neurological deficits, and potentially lead to severe disability. Globally, CCMs represent the second most common intracranial vascular malformation in humans, and their familial form (FCCMs) accounts for one-fifth of cases. Neurosurgical excision, and perhaps stereotactic radiosurgery, is the only available therapeutic option. Case reports suggest that propranolol might modify disease progression. Methods Treat_CCM is a prospective, randomized, open-label, blinded endpoint (PROBE), parallel-group trial involving six Italian clinical centres with central reading of brain magnetic resonance imaging (MRI) and adverse events. Patients with symptomatic FCCMs are randomized (2:1 ratio) either to propranolol (40–80 mg twice daily) in addition to standard care or to standard care alone (i.e. anti-epileptic drugs or headache treatments). The primary outcome is intracranial haemorrhage or focal neurological deficit attributable to CCMs. The secondary outcomes are MRI changes over time (i.e. de novo CCM lesions, CCM size and signal characteristics, iron deposition, and vascular leakage as assessed by quantitative susceptibility mapping and dynamic contrast enhanced permeability), disability, health-related quality of life, depression severity, and anxiety (SF-36, BDI-II, State-Trait Anxiety Inventory). Discussion Treat_CCM will evaluate the safety and efficacy of propranolol for CCMs following promising case reports in a randomized controlled trial. The direction of effect on the primary outcome and the consistency of effects on the secondary outcomes (even if none of them yield statistically significant differences) of this external pilot study may lead to a larger sample size in a definitive phase 2 trial. Trial registration ClinicalTrails.gov, NCT03589014. Retrospectively registered on 17 July 2018.
- Published
- 2020
4. Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis
- Author
-
Campanelli, R., Fois, G., Catarsi, P., Poletto, V., Villani, L., Erba, B. G., Maddaluno, L., Jemos, B., Salmoiraghi, S., Guglielmelli, P., Abbonante, V., Di Buduo, C. A., Balduini, A., Iurlo, A., Barosi, G., Rosti, V., Massa, M., Vannucchi, A. M., Balliu, M., Bartalucci, N., Bogani, C., Bosi, A., Calabresi, L., Corbizzi Fattori, G., Fanelli, T., Fjerza, R., Gesullo, F., Mannarelli, C., Merli, L., Pacilli, A., Pancrazzi, A., Paoli, C., Pieri, L., Rotunno, G., Sant'Antonio, E., Bonetti, E., Cazzola, M., Ambaglio, I., Bernasconi, P., Casetti, C. I., Catricala, S., Elena, C., Fugazza, E., Galli, A., Malcovati, L., Milanesi, C., Pascutto, C., Pietra, D., Ripamonti, F., Rossi, M., Rumi, E., Dejana, E., Breviario, F., Corada, M., Malinverno, M., Rambaldi, A., Chioda, G., Ferrari, M. L., Finazzi, G., Finazzi, M. C., Belotti, C., Boroni, C., Amaru, A., Golay, J., Bortoluzzi, S., Bisognin, A., Coppe, A., Saccoman, C., Manfredini, R., Artuso, L., Bernardis, I., Bianchi, E., Montanari, M., Pennucci, V., Prudente, Z., Rontauroli, S., Rossi, C., Ruberti, S., Salati, S., Tagliafico, E., Tenedini, E., and Zini, R.
- Subjects
Male ,0301 basic medicine ,Pathology ,Physiology ,Angiogenesis ,CD34 ,Gene Expression ,lcsh:Medicine ,Medicine (all) ,Biochemistry, Genetics and Molecular Biology (all) ,Agricultural and Biological Sciences (all) ,Cardiovascular Physiology ,Monocytes ,White Blood Cells ,0302 clinical medicine ,Animal Cells ,Immune Physiology ,Medicine and Health Sciences ,Blood and Lymphatic System Procedures ,Electron Microscopy ,lcsh:Science ,Microscopy ,Multidisciplinary ,Neovascularization, Pathologic ,Cell Differentiation ,Hematology ,Middle Aged ,Receptor, TIE-2 ,Haematopoiesis ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Splenectomy ,cardiovascular system ,Female ,Cellular Types ,Receptor ,Research Article ,medicine.medical_specialty ,Aged ,Case-Control Studies ,Humans ,Primary Myelofibrosis ,Spleen ,Patients ,Immune Cells ,CD14 ,Immunology ,Surgical and Invasive Medical Procedures ,Biology ,Research and Analysis Methods ,03 medical and health sciences ,Genetics ,medicine ,Progenitor cell ,TIE-2 ,Myelofibrosis ,Neovascularization ,Pathologic ,Blood Cells ,lcsh:R ,Biology and Life Sciences ,Cell Biology ,medicine.disease ,Hematopoiesis ,Health Care ,030104 developmental biology ,Transmission Electron Microscopy ,lcsh:Q ,Bone marrow ,Developmental Biology - Abstract
Primary myelofibrosis (PMF) is a Philadelphia-negative (Ph-) myeloproliferative disorder, showing abnormal CD34+ progenitor cell trafficking, splenomegaly, marrow fibrosis leading to extensive extramedullary haematopoiesis, and abnormal neoangiogenesis in either the bone marrow or the spleen. Monocytes expressing the angiopoietin-2 receptor (Tie2) have been shown to support abnormal angiogenic processes in solid tumors through a paracrine action that takes place in proximity to the vessels. In this study we investigated the frequency of Tie2 expressing monocytes in the spleen tissue samples of patients with PMF, and healthy subjects (CTRLs), and evaluated their possible role in favouring spleen angiogenesis. We show by confocal microscopy that in the spleen tissue of patients with PMF, but not of CTRLs, the most of the CD14+ cells are Tie2+ and are close to vessels; by flow cytometry, we found that Tie2 expressing monocytes were Tie2+CD14lowCD16brightCDL62-CCR2- (TEMs) and their frequency was higher (p = 0.008) in spleen tissue-derived mononuclear cells (MNCs) of patients with PMF than in spleen tissue-derived MNCs from CTRLs undergoing splenectomy for abdominal trauma. By in vitro angiogenesis assay we evidenced that conditioned medium of immunomagnetically selected spleen tissue derived CD14+ cells of patients with PMF induced a denser tube like net than that of CTRLs; in addition, CD14+Tie2+ cells sorted from spleen tissue derived single cell suspension of patients with PMF show a higher expression of genes involved in angiogenesis than that found in CTRLs. Our results document the enrichment of Tie2+ monocytes expressing angiogenic genes in the spleen of patients with PMF, suggesting a role for these cells in starting/maintaining the pathological angiogenesis in this organ.
- Published
- 2016
5. Acombination of CSF tau ratio and midsaggital midbraintopons atrophy for the earlydiagnosis of progressive supranuclear palsy
- Author
-
Borroni, Barbara, Malinverno, M, Gardoni, F, Grassi, M, Parnetti, L, Agosti, Chiara, Alberici, A, Premi, E, Bonuccelli, U, Gasparotti, Roberto, Calabresi, P, Di Luca, M, and Padovani, Alessandro
- Published
- 2010
6. Shoot and root architecture of young Populus nigra L. seedlings in response to mechanical stress applied to the taproot
- Author
-
DI IORIO, Antonino, Cappelletti, M., Malinverno, M., Montagnoli, Antonio, Scippa, G. S., and Chiatante, Donato
- Published
- 2007
7. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy
- Author
-
Ubaldo Bonuccelli, Matteo Malinverno, Enrico Premi, Daniela Perani, Antonella Alberici, M. Di Luca, Alessandro Padovani, Barbara Borroni, Lucilla Parnetti, Fabrizio Gardoni, Paolo Calabresi, Mario Grassi, Borroni, B, Malinverno, M, Gardoni, F, Alberici, A, Parnetti, L, Premi, E, Bonuccelli, U, Grassi, M, Perani, DANIELA FELICITA L., Calabresi, P, Di Luca, M, and Padovani, A.
- Subjects
Adult ,Lewy Body Disease ,Male ,Pathology ,medicine.medical_specialty ,Neurocognitive Disorders ,CSF ,tau Proteins ,Progressive supranuclear palsy ,Atrophy ,Cerebrospinal fluid ,Progressive Supranuclear Palsy ,Biomarker ,Protein Tau ,Isoforms ,Alzheimer Disease ,Predictive Value of Tests ,mental disorders ,medicine ,Humans ,Immunoprecipitation ,Corticobasal degeneration ,Aged ,Dementia with Lewy bodies ,Brain ,Reproducibility of Results ,Parkinson Disease ,Middle Aged ,medicine.disease ,eye diseases ,Case-Control Studies ,Biomarker (medicine) ,Dementia ,Female ,Supranuclear Palsy, Progressive ,Neurology (clinical) ,Alzheimer's disease ,Psychology ,Biomarkers ,Frontotemporal dementia - Abstract
Objective: In CSF, extended (55 kDa) and truncated (33 kDa) tau forms have been previously recognized, and the tau 33 kDa/55 kDa ratio has been found significantly reduced in progressive supranuclear palsy (PSP) vs in other neurodegenerative disorders. The aim of this study was to evaluate the diagnostic value of the CSF tau form ratio as a biomarker of PSP and to correlate the structural anatomic changes as measured by means of voxel-based morphometry (VBM) to CSF tau form ratio decrease. Methods: A total of 166 subjects were included in the study (21 PSP, 20 corticobasal degeneration syndrome, 44 frontotemporal dementia, 29 Alzheimer disease, 10 Parkinson disease, 15 dementia with Lewy bodies, and 27 individuals without any neurodegenerative disorder). Each patient underwent a standardized clinical and neuropsychological evaluation. In CSF, a semiquantitative immunoprecipitation was developed to evaluate CSF tau 33 kDa/55 kDa ratio. MRI assessment and VBM analysis was carried out. Results: Tau form ratio was significantly reduced in patients with PSP (0.504 ± 0.284) when compared to age-matched controls (0.989 ± 0.343), and to patients with other neurodegenerative conditions (range = 0.899–1.215). The area under the curve (AUC) of the receiver operating characteristic analysis in PSP vs other subgroups ranged from 0.863 to 0.937 (PSP vs others, AUC = 0.897, p Conclusions: Truncated tau production, which selectively affects brainstem neuron susceptibility, can be considered a specific and reliable marker for PSP. Tau form ratio was the lowest in progressive supranuclear palsy with no overlap with any other neurodegenerative illness. GLOSSARY: AD = Alzheimer disease; AUC = area under the curve; BADL = Basic Activity of Daily Living; CBDS = corticobasal degeneration; CON = controls; DLB = dementia with Lewy bodies; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th edition; FTD = frontotemporal dementia; IADL = Instrumental Activities of Daily Living; MMSE = Mini-Mental State Examination; MSA = multiple system atrophy; PD = Parkinson disease; PSP = progressive supranuclear palsy; ROC = receiver operating characteristic; UPDRS = Unified Parkinson’s Disease Rating Scale; VBM = voxel-based morphometry.
- Published
- 2008
8. A murine model of cerebral cavernous malformations with acute hemorrhage
- Author
-
Claudio Maderna, Federica Pisati, Claudio Tripodo, Elisabetta Dejana, Matteo Malinverno, Maderna C., Pisati F., Tripodo C., Dejana E., and Malinverno M.
- Subjects
Multidisciplinary ,Neurology ,Neurologi ,Developmental neuroscience, Model organism, Vascular remodeling ,Settore MED/08 - Anatomia Patologica - Abstract
Cavernomas are multi-lumen and blood-filled vascular malformations which form in the brain and the spinal cord. They lead to hemorrhage, epileptic seizures, neurological deficits, and paresthesia. An effective medical treatment is still lacking, and the available murine models for cavernomas have several limitations for preclinical studies. These include disease phenotypes that differ from human diseases, such as restriction of the lesions to the cerebellum, and absence of acute hemorrhage. Additional limitations of current murine models include rapid development of lesions, which are lethal before the first month of age. Here, we have characterized a murine model that recapitulates features of the human disease: lesions develop after weaning throughout the entire CNS, including the spinal cord, and undergo acute hemorrhage. This provides a preclinical model to develop new drugs for treatment of acute hemorrhage in the brain and spinal cord, as an unmet medical emergency for patients with cavernomas.
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.